News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
175,696 Results
Type
Article (7863)
Company Profile (23)
Press Release (167809)
Multimedia
Podcasts (16)
Webinars (2)
Section
Business (55974)
Career Advice (354)
Deals (9871)
Drug Delivery (26)
Drug Development (22424)
Employer Resources (32)
FDA (3674)
Job Trends (3955)
News (89079)
Policy (6350)
Tag
2027 BioCapital Standard (1)
2027 BioMidwest Elite (1)
2027 Biotech Beach Elite (1)
2027 Biotech Beach Standard (1)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Premier (1)
Academia (512)
Accelerated approval (16)
ADA (18)
Adcomms (10)
Allergies (55)
Alliances (5807)
ALS (60)
Alzheimer's disease (439)
Antibody-drug conjugate (ADC) (172)
Approvals (3944)
Artificial intelligence (104)
ASCO (193)
Autoimmune disease (114)
Automation (13)
Bankruptcy (70)
Best Places to Work (3550)
BIO (7)
BIOSECURE Act (4)
Biosimilars (57)
Biotechnology (16)
Bladder cancer (103)
Brain cancer (27)
Breast cancer (354)
Cancer (2417)
Cardiovascular disease (232)
Career advice (294)
Career pathing (3)
CAR-T (94)
CDC (9)
Celiac Disease (1)
Cell therapy (268)
Cervical cancer (23)
Clinical research (21192)
Collaboration (356)
Company closure (2)
Compensation (217)
Complete response letters (17)
COVID-19 (583)
CRISPR (76)
C-suite (119)
Cystic fibrosis (34)
Data (3720)
Depression (52)
Dermatology (47)
Diabetes (237)
Diagnostics (1690)
Digital health (11)
Diversity (3)
Diversity, equity & inclusion (12)
Drug discovery (67)
Drug pricing (27)
Drug shortages (4)
Duchenne muscular dystrophy (86)
Earnings (48360)
Editorial (14)
Employer branding (5)
Employer resources (26)
Events (35716)
Executive appointments (90)
FDA (4955)
Fibrodysplasia Ossificans Progressiva (3)
Friedreich's ataxia (6)
Frontotemporal dementia (15)
Funding (285)
Gene editing (141)
Generative AI (7)
Gene therapy (248)
GLP-1 (395)
Government (938)
Grass and pollen (1)
Guidances (340)
Healthcare (4865)
Hematology (66)
HIV (32)
Huntington's disease (21)
IgA nephropathy (58)
Immunology and inflammation (90)
Immuno-oncology (36)
Indications (77)
Infectious disease (686)
Inflammatory bowel disease (65)
Inflation Reduction Act (2)
Influenza (43)
Intellectual property (49)
Interviews (69)
IPO (6182)
IRA (8)
Job creations (585)
Job search strategy (255)
JPM (7)
Kidney cancer (13)
Labor market (30)
Layoffs (167)
Leadership (4)
Legal (1183)
Liver cancer (35)
Longevity (4)
Lung cancer (359)
Lymphoma (249)
Machine learning (13)
Management (10)
Manufacturing (161)
MASH (88)
Medical device (3286)
Medtech (3327)
Mergers & acquisitions (4043)
Metabolic disorders (616)
mRNA (43)
Multiple sclerosis (79)
NASH (9)
Neurodegenerative disease (110)
Neuropsychiatric disorders (34)
Neuroscience (914)
NextGen: Class of 2026 (1325)
Non-profit (874)
Now hiring (17)
Obesity (291)
Opinion (46)
Ovarian cancer (76)
Pain (58)
Pancreatic cancer (111)
Parkinson's disease (114)
Partnered (5)
Patents (103)
Patient recruitment (150)
Peanut (16)
People (5269)
Pharmaceutical (6)
Pharmacy benefit managers (8)
Phase 1 (5537)
Phase 2 (8839)
Phase 3 (8633)
Pipeline (4499)
Policy (43)
Postmarket research (848)
Preclinical (1932)
Press Release (16)
Prostate cancer (108)
Psychedelics (13)
Radiopharmaceuticals (97)
Rare diseases (352)
Real estate (652)
Recruiting (8)
Regulatory (5687)
Reports (17)
Research institute (429)
Resumes & cover letters (52)
Rett syndrome (34)
RNA editing (7)
RSV (33)
Schizophrenia (64)
Series A (37)
Series B (24)
Sickle cell disease (60)
Special edition (9)
Spinal muscular atrophy (41)
Sponsored (9)
Startups (530)
State (1)
Stomach cancer (7)
Supply chain (24)
Tariffs (13)
The Weekly (16)
Vaccines (284)
Venture capital (23)
Weight loss (225)
Women's health (45)
Worklife (5)
Date
Today (19)
Last 7 days (81)
Last 30 days (762)
Last 365 days (9961)
2026 (5000)
2025 (10060)
2024 (11376)
2023 (12820)
2022 (15347)
2021 (15098)
2020 (13776)
2019 (10991)
2018 (8211)
2017 (8221)
2016 (7144)
2015 (8990)
2014 (6199)
2013 (4618)
2012 (5210)
2011 (5393)
2010 (4871)
Location
Africa (150)
Alabama (26)
Alaska (1)
Arizona (76)
Arkansas (1)
Asia (10879)
Australia (1571)
California (4369)
Canada (1219)
China (563)
Colorado (214)
Connecticut (173)
Delaware (193)
Europe (24536)
Florida (549)
Georgia (163)
Hawaii (1)
Idaho (8)
Illinois (328)
India (27)
Indiana (277)
Iowa (3)
Japan (233)
Kansas (39)
Kentucky (13)
Louisiana (25)
Maine (51)
Maryland (444)
Massachusetts (3216)
Michigan (79)
Minnesota (195)
Missouri (43)
Montana (8)
Nebraska (2)
Nevada (38)
New Hampshire (19)
New Jersey (1461)
New Mexico (2)
New York (1135)
North Carolina (491)
North Dakota (2)
Northern California (2328)
Ohio (104)
Oklahoma (5)
Oregon (3)
Pennsylvania (919)
Puerto Rico (7)
Rhode Island (8)
South America (251)
South Carolina (9)
Southern California (1677)
Tennessee (37)
Texas (673)
United States (15388)
Utah (109)
Virginia (57)
Washington D.C. (15)
Washington State (329)
West Virginia (1)
Wisconsin (32)
175,696 Results for "9".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
RNA editing
Lilly targets kidney disease with Ascidian’s RNA exon editors for up to $1.9B
For an investment of up to $1.9 billion, Eli Lilly will be able to use Ascidian Therapeutics’ platform that removes mutated exons from mRNA molecules, avoiding the expression of disease-causing proteins.
June 3, 2026
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
Chiesi snaps up KalVista for $1.9B, betting big on rare disease med Ekterly
Chiesi Group is taking KalVista Pharmaceuticals under its wing, paying $1.9 billion for the biotech’s oral therapy Ekterly to treat severe swelling episodes caused by the rare genetic disorder hereditary angioedema.
April 29, 2026
·
2 min read
·
Gabrielle Masson
Press Releases
IRLAB Participates at Aktiedagarna in Stockholm on June 9
June 3, 2026
·
1 min read
Press Releases
Calidi Biotherapeutics Announces Investor Webinar on June 9, 2026
June 8, 2026
·
3 min read
Deals
Lilly deepens relationship with China’s Abbisko for $1.9B biobucks
Lilly has already spent more than $25 billion in potential business development commitments this year, including the $6.3 billion buyout of Centessa Pharmaceuticals that closed today.
June 24, 2026
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
AbbVie strikes $10.9B Apogee buy to challenge juggernaut Dupixent
AbbVie will add Apogee’s IL-23 blocker to its current immunology stalwarts Skyrizi and Rinvoq, which have helped the pharma ride out the steep patent cliff left behind from mega-blockbuster drug Humira.
June 22, 2026
·
2 min read
·
Tristan Manalac
Deals
Novartis, Antares stars align in cancer deal that could top $1.9B
Novartis and Antares Therapeutics are shooting for the stars, launching a joint mission to develop small molecule oncology therapies.
June 24, 2026
·
2 min read
·
Gabrielle Masson
Press Releases
POP Biotechnologies Secures Up to $9.7 Million in CEPI Funding
June 4, 2026
·
6 min read
Press Releases
Arcus Biosciences Announces New Employment Inducement Grants - June 9, 2026
June 10, 2026
·
1 min read
Press Releases
Summit Therapeutics Announces Proposed Public Offering of Common Stock - June 9, 2026
June 10, 2026
·
5 min read
1 of 17,570
Next
